Integra LifeSciences
IART
211 hedge funds and large institutions have $2.67B invested in Integra LifeSciences in 2016 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 79 increasing their positions, 73 reducing their positions, and 16 closing their positions.
2,779% more call options, than puts
Call options by funds: $2.99M | Put options by funds: $104K
113% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 16
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more capital invested
Capital invested by funds: $2.22B → $2.67B (+$455M)
8% more funds holding
Funds holding: 195 → 211 (+16)
8% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
+$51.1M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$36.8M |
| 3 |
CCI
Columbus Circle Investors
|
+$28.4M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$23.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$22.1M |
| 2 |
EIP
Epoch Investment Partners
New York
|
-$20M |
| 3 |
FA
Friess Associates
Greenville,
Delaware
|
-$19M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$15.9M |
| 5 |
Millennium Management
New York
|
-$15.5M |
IART Hedge Fund Activity: Q2 2016 in Review
211 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2016, worth a combined $2.67B — up 21% from $2.22B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new IART positions and 16 closed out — a net gain of 18 holders — while 79 added to existing stakes and 73 trimmed.
The largest buyer was RS Investment Management, opening a new position worth an estimated $51.1M. The largest seller was Victory Capital Management, exiting entirely with an estimated $22.1M sold.
- 211 institutional investors held Integra LifeSciences (IART) as of Q2 2016, up from 195 in Q1 2016.
- Funds reported $2.67B of Integra LifeSciences stock for Q2 2016, up 21% quarter-over-quarter.
- 34 funds opened new Integra LifeSciences positions in Q2 2016 and 16 closed out, a net change of +18 holders.
- The largest Integra LifeSciences buyer in Q2 2016 was RS Investment Management, an estimated $51.1M added.
- The largest Integra LifeSciences seller in Q2 2016 was Victory Capital Management, an estimated $22.1M sold.
Based on aggregated 13F filings for Q2 2016.